Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 4/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110500 | 0.91 | PPARG (0.45) | PPARGL3MBTL1P2RX3ACACBLIPE | |
| SCHEMBL5120370 | 0.90 | PPARG (0.58) | PPARGSMN1; SMN2LMNA | |
| SCHEMBL5112219 | 0.89 | PPARG (0.43) | PPARGL3MBTL1P2RX3ACACBLIPE | |
| SCHEMBL5113115 | 0.86 | PPARG (0.46) | PPARGP2RX3SMN1; SMN2LMNA | |
| SCHEMBL5107810 | 0.85 | PPARG (0.45) | PPARGL3MBTL1ACACBLIPEBCHE | |
| SCHEMBL5113771 | 0.82 | PPARG (0.59) | PPARGL3MBTL1ACACBLIPEBCHE | |
| SCHEMBL5120082 | 0.82 | PPARG (0.61) | PPARGSMN1; SMN2 | |
| SCHEMBL5113868 | 0.82 | PPARG (0.54) | PPARGSMN1; SMN2 | |
| SCHEMBL5109443 | 0.81 | PPARG (0.58) | PPARGSMN1; SMN2 | |
| SCHEMBL5120850 | 0.81 | PPARG (0.47) | PPARGL3MBTL1ACACBLIPEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885L3MBTL1 2694/4885P2RX3 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.